Absci (ABSI) Cash from Financing Activities (2020 - 2026)
Absci's (ABSI) quarterly Cash from Financing Activities came in at $7.6 million in Q1 2026, down 82.34% year-on-year from $42.8 million in Q1 2025, and up 96.67% quarter-over-quarter from $3.8 million in Q4 2025.
Absci (ABSI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Absci has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $7.6 million for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $7.6 million, down 82.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $70.7 million (up 60.21% YoY), and the FY2025 annual result was $105.9 million, up 28.38% from the prior year.
- Cash from Financing Activities came in at $7.6 million for Q1 2026 at Absci, up from $3.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $81.2 million in Q1 2024 to a low of -$1.2 million in Q4 2023.
- The 5-year median for Cash from Financing Activities is $490000.0 (2024), against an average of $11.6 million.
- Peak annual rise in Cash from Financing Activities reached 12209.59% in 2025, while the deepest fall reached 649.25% in 2025.
- Absci's Cash from Financing Activities stood at $1.4 million in 2022, then slumped by 188.66% to -$1.2 million in 2023, then jumped by 179.84% to $986000.0 in 2024, then jumped by 289.66% to $3.8 million in 2025, then surged by 96.67% to $7.6 million in 2026.
- The last three Cash from Financing Activities figures came in at $7.6 million (Q1 2026), $3.8 million (Q4 2025), and $60.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Absci | 1.13 Bn | 1.01 Bn | - | 7.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.56 Mn |
| Mar 31, 2026 | 7.56 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 60.32 Mn |
| Sep 30, 2025 | 60.32 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Mar 31, 2025 | 42.79 Mn |
| Mar 31, 2025 | 42.79 Mn |
| Dec 31, 2024 | 986,000.00 |
| Dec 31, 2024 | 986,000.00 |
| Sep 30, 2024 | 490,000.00 |
| Sep 30, 2024 | 490,000.00 |
| Jun 30, 2024 | -134,000.00 |
| Jun 30, 2024 | -134,000.00 |
| Mar 31, 2024 | 81.18 Mn |
| Mar 31, 2024 | 81.18 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Dec 31, 2023 | -1.24 Mn |